Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRI GRI Bio	$1.40 +0.7%	$1.53	$1.10 ▼ $30.43	$3.50M	-1.61	225,935 shs	83,980 shs
LSDI Lucy Scientific Discovery		$0.03	$0.44 ▼ $12.80	$907K	1.41	640,390 shs	314,500 shs
NBY NovaBay Pharmaceuticals	$0.91 -14.9%	$0.64	$0.44 ▼ $1.25	$5.30M	0.4	1.31 million shs	1.67 million shs
SRNE Sorrento Therapeutics	$0.00 -24.6%	$0.00	$0.00 ▼ $0.02	$2.37M	0.85	121,918 shs	70,004 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRI GRI Bio	+0.72%	+0.72%	-31.37%	+16.67%	-83.57%
LSDI Lucy Scientific Discovery	0.00%	0.00%	0.00%	0.00%	+2,469.50%
NBY NovaBay Pharmaceuticals	-14.94%	+47.38%	+38.84%	+59.75%	+68.23%
SRNE Sorrento Therapeutics	-24.56%	+104.76%	+230.77%	+230.77%	-57.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GRI GRI Bio	1.7604 of 5 stars	3.5	2.0	0.0	0.0	1.5	0.0	0.6
LSDI Lucy Scientific Discovery	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	0.3869 of 5 stars	1.5	0.0	0.0	0.0	0.6	0.0	1.3
SRNE Sorrento Therapeutics	0.703 of 5 stars	0.0	2.0	0.0	4.3	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRI GRI Bio	3.00	Buy	$22.00	1,471.43% Upside
LSDI Lucy Scientific Discovery	0.00	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	-6.60% Downside
SRNE Sorrento Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LSDI, GRI, SRNE, and NBY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/11/2025	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/27/2025	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $34.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRI GRI Bio	N/A	N/A	N/A	N/A	$1.32 per share	N/A
LSDI Lucy Scientific Discovery	$16.73K	0.00	N/A	N/A	$2.86 per share	0.00
NBY NovaBay Pharmaceuticals	$9.78M	0.54	N/A	N/A	$4.25 per share	0.21
SRNE Sorrento Therapeutics	$60.32M	0.04	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRI GRI Bio	-$8.21M	-$11.56	N/A	N/A	N/A	N/A	-327.62%	-191.40%	N/A
LSDI Lucy Scientific Discovery	-$8.99M	-$7.00	N/A	N/A	N/A	N/A	-294.74%	-137.65%	N/A
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest LSDI, GRI, SRNE, and NBY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	GRI GRI Bio	-$1.31	-$1.31	N/A	-$1.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
LSDI Lucy Scientific Discovery	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRI GRI Bio	N/A	2.41	1.41
LSDI Lucy Scientific Discovery	N/A	0.38	0.38
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91
SRNE Sorrento Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRI GRI Bio	33.95%
LSDI Lucy Scientific Discovery	72.61%
NBY NovaBay Pharmaceuticals	23.25%
SRNE Sorrento Therapeutics	0.02%

Insider Ownership

Company	Insider Ownership
GRI GRI Bio	0.87%
LSDI Lucy Scientific Discovery	N/A
NBY NovaBay Pharmaceuticals	0.10%
SRNE Sorrento Therapeutics	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRI GRI Bio	1	2.52 million	2.49 million	Not Optionable
LSDI Lucy Scientific Discovery	2	1.77 million	N/A	Not Optionable
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data

LSDI, GRI, SRNE, and NBY Headlines

Recent News About These Companies

Sorrento Therapeutics Inc (SRNE) - Investing.com

July 3, 2025 | investing.com

SRNE Sorrento Therapeutics, Inc. - Seeking Alpha

June 29, 2025 | seekingalpha.com

Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga

April 19, 2025 | benzinga.com

Sorrento Shareholders Lose Discovery Bid Over Judge Relationship

March 28, 2025 | news.bloomberglaw.comN

Scilex says bankruptcy court extends lockup period on shares of Scilex dividend

January 31, 2025 | markets.businessinsider.com

DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills

October 24, 2024 | newsfilecorp.comN

Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says

August 20, 2024 | msn.com

Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter

May 29, 2024 | newsfilecorp.comN

Sorrento Therapeutics Inc (SRNE)

May 25, 2024 | investing.com

Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person

May 8, 2024 | newsfilecorp.comN

DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing

May 1, 2024 | newsfilecorp.comN

Sorrento Therapeutics Inc SRNE

April 26, 2024 | morningstar.comM

Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks

March 27, 2024 | news.bloomberglaw.comN

Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks

March 27, 2024 | news.bloomberglaw.comN

Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)

March 12, 2024 | news.bloomberglaw.comN

Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case

March 12, 2024 | wsj.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 27, 2024 | tmcnet.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 27, 2024 | businesswire.com

Sorrento Therapeutics

February 7, 2024 | pharmaphorum.comP

5 Sanders Cove, Sorrento WA 6020

January 18, 2024 | domain.com.auD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LSDI, GRI, SRNE, and NBY Company Descriptions

GRI Bio NASDAQ:GRI

$1.40 +0.01 (+0.72%)

As of 08/22/2025 04:00 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Lucy Scientific Discovery NASDAQ:LSDI

Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.

NovaBay Pharmaceuticals NYSE:NBY

$0.91 -0.16 (-14.94%)

As of 08/22/2025 04:00 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Sorrento Therapeutics NASDAQ:SRNE

$0.0043 0.00 (-24.56%)

As of 08/22/2025 03:59 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time